Satellos Bioscience Inc

As of June 30, 2026, Satellos Bioscience Inc carries a market capitalization of 222.06M, placing it among publicly traded companies globally. Its enterprise value stands at 134.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Satellos Bioscience Inc's next confirmed earnings release is scheduled for November 25, 2026.

As of June 30, 2026, Satellos Bioscience Inc has 20.83M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Satellos Bioscience Inc maintains a current ratio of 11.22, meaning it holds 11.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Satellos Bioscience Inc posted a negative return on equity (ROE) of -70.45, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -64.76, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Satellos Bioscience Inc recorded 218,558.34 in income tax expense. The company reported a pretax loss of -48.90M and -49.12M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Satellos Bioscience Inc's stock has gained approximately 2.70% over the past 52 weeks. The 50-day moving average sits at 12.21, while the 200-day moving average is 11.77.

Over the twelve months ended June 30, 2026, Satellos Bioscience Inc generated - - in revenue and converted that into -49.12M in net income, yielding earnings per share of -2.86. EBITDA reached -50.83M, while operating income came in at -50.84M.

These figures are as of June 30, 2026. Total book value stands at 85.02M, with working capital of 85.01M providing operational flexibility.

Satellos Bioscience Inc produced -41.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9,934.47 in capital expenditures, free cash flow totaled -41.17M - equivalent to -2.40 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -22.49: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -33.74, meaning Satellos Bioscience Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Satellos Bioscience Inc's most recent stock split took place on January 30, 2026 with a 12:1 split ratio.

As of June 30, 2026, Satellos Bioscience Inc has an Altman Z-Score of 13.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.